In today’s ACT Brief, we examine how capturing friction in real time can reveal site burden, how OpenAI and Mistral compare on clinical trial matching, and how Boehringer Ingelheim is licensing early-stage oncology programs from SBP Group.
|Webcasts|July 21, 2020
Applying Virtual Approaches to Dermatology Trials
Adoption of remote and virtual trial tools is helping to ensure the safety of dermatology patients during the pandemic. IQVIA Biotech shares how incorporating patient-centric approaches in future dermatology trials can increase patient access and engagement. Live: Tuesday, Jul. 21, 2020 at 11am EDT On demand available after airing until Jul. 21, 2021. Register free
Register free:
Event Overview:
Dermatology patients are eager to participate in trials from their homes during the COVID-19 pandemic. Sponsors and investigators managing dermatology clinical trials have quickly embraced remote and virtual tools to keep patients safe and keep trials moving forward.
Join our webinar and learn how to incorporate virtual approaches into the design and delivery of dermatology trials – to lower overall study risks and increase patient engagement.
Our experts will share:
- Lessons learned from ongoing dermatology trials due to COVID-19
- Innovative and flexible approaches that reduce patient and site burden, and improve the overall patient experience
- How to determine the right virtual/hybrid model for your clinical trial
Key Learnings
- Discover insights from the adoption of remote and virtual trial tools during the COVID-19 pandemic that are now leading to more patient-centric dermatology trials
- Recognize practical solutions to reduce the operational risks of dermatology trials while increasing patient safety
- Evaluate options such as telemedicine and connected devices to improve the clinical trial experience for dermatology patients, leading to improved recruitment and retention
Speakers: Sonja VanWye, RN, MSN, Director of Dermatology Strategy, IQVIA Biotech
Christopher Varner, Virtual Trials Project Manager, IQVIA
Jeff Bagshaw, Vice President, Global Business Development, IQVIA Biotech
Time and date: Tuesday, Jul. 21, 2020 at 11am EDT
On demand available after airing until Jul. 21, 2021.
Sponsor: IQVIA
Register free:
Related to this article
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.
ACT Brief: Community Research Financing Gaps, Neuroscience Endpoint Data, and Teva’s Biosimilar Deal
In today’s ACT Brief, we examine why community research needs lasting financing and infrastructure, how electronic outcome tools can strengthen neuroscience endpoints, and how Teva is licensing two biosimilars from Samsung Bioepis.
Neuroscience trials struggle to show benefit because symptoms are subjective and variable, and eCOA strengthens dossiers by standardizing ClinRO administration, capturing outcomes in real time to reduce recall bias, and adding patient and caregiver perspectives that clinician scales miss.
Community participation gaps look less like a question of patient willingness and more like a financing and infrastructure problem that no single bill has yet solved.
In today’s ACT Brief, we examine what changes when AI is embedded across clinical operations, why faster trial data isn’t yet producing faster decisions, and how FDA granted accelerated approval to a therapy for a rare airway disease.
Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
Trending on Applied Clinical Trials Online
1
Comparing OpenAI and Mistral on Clinical Trial Matching
2
Embedding AI Across the Clinical Operating Model: Q&A with Rajneesh Patil, Syneos Health
3
From Complexity to Endpoint Meaningfulness: Addressing Key Neuroscience Trial Challenges with eCOA
4
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
5